Bladder chemo plus pembrolizumab for BCG-treated cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of high-risk non-muscle invasive bladder cancer (types T1, high-grade Ta, or CIS).
- You must have been treated with a full course of BCG therapy (at least 5 of 6 induction doses and 7 of 9 maintenance doses within 9 months).
- Your cancer must have not responded to BCG or come back within a certain time after BCG (for example, within 12 months for unresponsive or 24 months for exposed).
- You must have had a complete removal of any visible papillary tumors (Ta or T1) before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This phase 1 trial tests a new treatment for early-stage bladder cancer that has not responded to BCG therapy. The treatment is given directly into the bladder (intravesical), which may help avoid removing the bladder.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (gemcitabine) given directly into the bladder after surgery to remove high-risk bladder tumors. The goal is to reduce the chance of the cancer coming back.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.